HUP0002533A2 - New combination of antiasthma medicaments - Google Patents
New combination of antiasthma medicamentsInfo
- Publication number
- HUP0002533A2 HUP0002533A2 HU0002533A HUP0002533A HUP0002533A2 HU P0002533 A2 HUP0002533 A2 HU P0002533A2 HU 0002533 A HU0002533 A HU 0002533A HU P0002533 A HUP0002533 A HU P0002533A HU P0002533 A2 HUP0002533 A2 HU P0002533A2
- Authority
- HU
- Hungary
- Prior art keywords
- preparation
- solvate
- pharmaceutically acceptable
- inhalation
- component selected
- Prior art date
Links
- 230000001088 anti-asthma Effects 0.000 title 1
- 239000000924 antiasthmatic agent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 abstract 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 abstract 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 abstract 1
- 229950004432 rofleponide Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány tárgya terápiás készítmény, amely tartalmaz a) aformoterol, annak gyógyszerészetileg elfogadható sója vagy szolvátjaés a só szolvátja közül választott első hatóanyag-komponenst; b) arofleponid és annak egy zsírsav-észtere közül választott másodikhatóanyag-komponenst; ahol a készítményben a) és b) mólaránya 1:1 és1:100 között van. A készítményben a) előnyösen formoterol-fumarát-dihidrát; b) előnyösen rofleponid-palmitát. A száraz por formájúkészítmény tartalmaz továbbá gyógyszerészetileg elfogadható,inhalálásra alkalmas segédanyagot, hígítószert vagy hordozót. Arészecskék tömeg szerinti átlagos átmérője 10 mm-nél kisebb. Akészítményt légzési rendellenességek, köztük az asztma kezelésérealkalmazzák, főként inhalációs formában a hatóanyag-komponensekegyidejű vagy egymás utáni beadásával. ÓThe subject of the invention is a therapeutic composition, which contains a) a first active component selected from aformoterol, its pharmaceutically acceptable salt or solvate, and the solvate of the salt; b) a second active substance component selected from arofleponide and a fatty acid ester thereof; where the molar ratio of a) and b) in the composition is between 1:1 and 1:100. In the preparation a) preferably formoterol fumarate dihydrate; b) preferably rofleponide palmitate. The preparation in the form of a dry powder also contains a pharmaceutically acceptable excipient suitable for inhalation, a diluent or a carrier. The average diameter of the particles by weight is less than 10 mm. The preparation is used to treat breathing disorders, including asthma, mainly in inhalation form with the simultaneous or sequential administration of the active ingredients. HE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88382397A | 1997-06-27 | 1997-06-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0002533A2 true HUP0002533A2 (en) | 2000-12-28 |
| HUP0002533A3 HUP0002533A3 (en) | 2001-03-28 |
Family
ID=25383399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0002533A HUP0002533A3 (en) | 1997-06-27 | 1998-06-08 | New combination of antiasthma medicaments |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1009408A1 (en) |
| JP (1) | JP2002510310A (en) |
| KR (1) | KR20010014162A (en) |
| AU (1) | AU8135098A (en) |
| BR (1) | BR9810452A (en) |
| CA (1) | CA2295076A1 (en) |
| EE (1) | EE9900594A (en) |
| HU (1) | HUP0002533A3 (en) |
| ID (1) | ID24063A (en) |
| IL (1) | IL133597A0 (en) |
| IS (1) | IS5303A (en) |
| NO (1) | NO996438L (en) |
| PL (1) | PL337722A1 (en) |
| SK (1) | SK184799A3 (en) |
| TR (1) | TR199903272T2 (en) |
| WO (1) | WO1999000134A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9703407D0 (en) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (en) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| SE9900833D0 (en) * | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| GB0009617D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009607D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medical compositions |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9302777D0 (en) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| DK0613371T3 (en) * | 1991-12-18 | 2002-05-13 | Astrazeneca Ab | New combination of formoterol and budesonide |
| AR002009A1 (en) * | 1994-12-22 | 1998-01-07 | Astra Ab | PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE MANUFACTURE OF A PROLIPOSOMA POWDER AS USED IN SUCH COMPOSITION, PROCEDURE FOR LAMANUFACTURE OF SUCH COMPOSITION, USE OF SUCH PHARMACEUTICAL COMPOSITION IN THE MANUFACTURE OF A DISPOSAL MEDICINAL PRODUCT. |
| SE9501384D0 (en) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| SE9603669D0 (en) * | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
-
1998
- 1998-06-08 AU AU81350/98A patent/AU8135098A/en not_active Abandoned
- 1998-06-08 PL PL98337722A patent/PL337722A1/en unknown
- 1998-06-08 CA CA002295076A patent/CA2295076A1/en not_active Abandoned
- 1998-06-08 IL IL13359798A patent/IL133597A0/en unknown
- 1998-06-08 BR BR9810452-7A patent/BR9810452A/en not_active IP Right Cessation
- 1998-06-08 EE EEP199900594A patent/EE9900594A/en unknown
- 1998-06-08 EP EP98931163A patent/EP1009408A1/en not_active Withdrawn
- 1998-06-08 TR TR1999/03272T patent/TR199903272T2/en unknown
- 1998-06-08 ID IDW991684A patent/ID24063A/en unknown
- 1998-06-08 WO PCT/SE1998/001089 patent/WO1999000134A1/en not_active Application Discontinuation
- 1998-06-08 HU HU0002533A patent/HUP0002533A3/en unknown
- 1998-06-08 SK SK1847-99A patent/SK184799A3/en unknown
- 1998-06-08 JP JP50547999A patent/JP2002510310A/en active Pending
- 1998-06-08 KR KR1019997012233A patent/KR20010014162A/en not_active Application Discontinuation
-
1999
- 1999-12-15 IS IS5303A patent/IS5303A/en unknown
- 1999-12-23 NO NO996438A patent/NO996438L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SK184799A3 (en) | 2000-06-12 |
| NO996438L (en) | 2000-02-28 |
| ID24063A (en) | 2000-07-06 |
| KR20010014162A (en) | 2001-02-26 |
| CA2295076A1 (en) | 1999-01-07 |
| JP2002510310A (en) | 2002-04-02 |
| NO996438D0 (en) | 1999-12-23 |
| AU8135098A (en) | 1999-01-19 |
| WO1999000134A1 (en) | 1999-01-07 |
| IS5303A (en) | 1999-12-15 |
| BR9810452A (en) | 2000-09-05 |
| EP1009408A1 (en) | 2000-06-21 |
| EE9900594A (en) | 2000-08-15 |
| PL337722A1 (en) | 2000-08-28 |
| IL133597A0 (en) | 2001-04-30 |
| HUP0002533A3 (en) | 2001-03-28 |
| TR199903272T2 (en) | 2000-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU90392I2 (en) | A combination comprising salmeterol optionally in the form of a pharmaceutically acceptable salt including 1-hydroxy-2-naphthoate (xinafoate) and fluticasone propionate | |
| HUP0003848A2 (en) | New use for budesonide and formoterol | |
| SI9200403B (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
| CA2195065A1 (en) | Inhalation composition | |
| HUP0203728A2 (en) | Aerosol composition comprising formoterol | |
| CA2125665A1 (en) | Medicaments | |
| MY125662A (en) | Pharmaceutical formulations containing darifenacin | |
| ZA876731B (en) | Therapeutic agents | |
| CA2024872A1 (en) | Medicaments | |
| CA2240717A1 (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| HUP0002533A2 (en) | New combination of antiasthma medicaments | |
| ATE91890T1 (en) | MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM. | |
| CA2456721A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| JPS6360926A (en) | Cold remedy | |
| RU2000100309A (en) | A NEW COMBINATION OF ANTI-ASTHASTIC MEDICINES | |
| MY111155A (en) | Medicaments | |
| RU98108621A (en) | NEW COMBINATION | |
| TH59260B (en) | Dosing of the active ingredient that has been aerosolized | |
| TH21055A (en) | Pharmaceutical mixtures for inhalation action. | |
| TH51541A (en) | New mixtures of substances |